- Home
- AHG vs VTYX Comparison
AHG vs VTYX Comparison
Compare AHG & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | VTYX |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 990.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AHG | VTYX |
|---|---|---|
| Price | $1.35 | $13.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 2.7K | ★ 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $0.90 |
| 52 Week High | $2.10 | $15.34 |
Technical Indicators
Market Signals| Indicator | AHG | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 72.58 |
| Support Level | $1.24 | $13.89 |
| Resistance Level | $1.67 | $14.07 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 37.04 | 88.89 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.